当前位置: 首页 > 期刊 > 《医药产业资讯》 > 201815
编号:13583446
IgA肾病残余蛋白尿非免疫抑制剂药物治疗进展(5)
http://www.100md.com 2018年5月25日 《中国医药导报》 201815
     [27] Moriyama T,Oshima Y,Tanaka K,et al. Statins stabilize the renal function of IgA nephropathy [J]. Ren fail,2014, 36﹙3﹚:356-360.

    [28] Rosselli J,Thacker SM,Karpinski JP,et al. Treatment of IgA nephropathy:an update [J]. Ann Pharmacother,2011, 45﹙10﹚:1284-1296.

    [29] Tian J,Chen JH,Li Q,et al. Lipid peroxidation in IgA nephropathy and the effect of lipo-prostaglandin E1 [J]. J Nephrol,2005,18﹙3﹚:243-248.

    [30] Chen XM,Qiu Q,Tang L,et al. Effects of co-administration of urokinase and benazepril on severe IgA nephropathy [J]. Nephrol Dial Transplant,2004,19﹙4﹚:852-857.

    [31] Ye ZM,Zhang L,Xu LX,et al. Probucol combined with valsartan in immunoglobulin a nephropath:a multi-centre,open labelled,randomized controlled study [J]. Nephrology,2014,19﹙1﹚:40-46.

    [32] 李雯雯,沈沛成.IgA肾病的中医药研究进展[J].西部中醫药,2017,30﹙6﹚:143-146.

    [33] 王丽红,陈彤,李薇,等.吗替麦考酚酯联合激素治疗血管炎性IgA肾病患者的效果及对24h尿蛋白、血肌酐等的影响[J].疑难病杂志,2016,15(11):1143-1146.

    (收稿日期:2018-02-11 本文编辑:苏 畅), 百拇医药(胡妍琦 李六生)
上一页1 2 3 4 5